Mondrian Investment Partners LTD cut its stake in Johnson & Johnson (NYSE:JNJ) by 7.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 686,893 shares of the company’s stock after selling 54,926 shares during the period. Johnson & Johnson accounts for 2.0% of Mondrian Investment Partners LTD’s investment portfolio, making the stock its 13th largest position. Mondrian Investment Partners LTD’s holdings in Johnson & Johnson were worth $83,320,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently modified their holdings of the company. Americafirst Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter valued at about $101,000. INR Advisory Services LLC acquired a new position in Johnson & Johnson during the second quarter valued at about $150,000. Stelac Advisory Services LLC acquired a new position in Johnson & Johnson during the first quarter valued at about $192,000. Capital Asset Advisory Services LLC acquired a new position in Johnson & Johnson during the second quarter valued at about $202,000. Finally, NewSquare Capital LLC raised its position in Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock valued at $217,000 after buying an additional 83 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.73% on Friday, reaching $118.13. 7,941,065 shares of the company traded hands. The company has a 50-day moving average of $119.23 and a 200-day moving average of $116.66. Johnson & Johnson has a 1-year low of $92.58 and a 1-year high of $126.07. The stock has a market capitalization of $323.19 billion, a price-to-earnings ratio of 22.01 and a beta of 0.61.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The company earned $18.50 billion during the quarter, compared to analysts’ expectations of $17.98 billion. Analysts anticipate that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were issued a $0.80 dividend. The ex-dividend date of this dividend was Friday, August 19th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.71%. Johnson & Johnson’s dividend payout ratio is currently 60.15%.
Several equities analysts have recently issued reports on JNJ shares. BTIG Research reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Friday, June 3rd. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $109.97 target price for the company. in a report on Monday, June 6th. Wells Fargo & Co. reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, June 6th. Goldman Sachs Group Inc. set a $121.00 target price on shares of Johnson & Johnson and gave the company a “neutral” rating in a report on Monday, June 13th. Finally, Jefferies Group reiterated a “hold” rating and set a $109.00 target price (up from $108.00) on shares of Johnson & Johnson in a report on Tuesday, June 14th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $120.19.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of the firm’s stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the transaction, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the transaction, the vice president now directly owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.